Thanks for the question Rudee.
As far as I'm aware there's no resistance to using ResAppDx where the clinical situation requires, but I must qualify that I know very little about what happens outside my practice. Like the rest of you, I rely on figures reported by Coviu, and estimate ResAppDx usage from that.
I do need to point out, however, that only 10% of telehealth consults are conducted by video, where ResAppDx can be used. With the rest of the 90% where only phone is used ResAppDx is simiply not accessible. The uptake of video consults, rather than ResAppDx per se, is an issue which requires further work. I remember
@MAX25 did point out a few months ago, that the bottleneck in telehealth uptake is the availability of technology, internet bandwidth, as well as customer and doctor's expertise in utilizing these technologies. I think the 10% video consult number is a reflection of this technology bottleneck, and any short term limitation to ResAppDx uptake would probably be due to this rather than ResAppDx itself.
Due to this, my current thought is that we should remain conservative with our estimate of the use and revenue generated by ResAppDx in the current quarter. On this I agree with the conservative estimate made by
@kenjikool.
On the other side of the argument, it's equally important to note that, despite the measly 10% video utilization, Coviu was already conducting 25,000 video consults in April 2020. If you look at this from a "glass half full" perspective, with the 25,000 consults per day representing only 10% market penetration of video consults, with each 10% increment of video consults adoption, Coviu can expect another 25,000 per day. Coviu continues to report strong interest and growth, so whilst I like to err on the conservative side, I believe all should be going well. There is certainly still a long growth runway, even if you only consider Australia.
https://aicd.companydirectors.com.au/membership/company-director-magazine/2020-back-editions/august/how-telehealth-company-coviu-used-the-pandemic-to-boost-their-business.
It is also important to note that, whilst better technology, better internet, better workflow at the patient's and doctor's ends will all help increase adoption of video consults, the availability and demand for critical diagnostic tools like ResAppDx, should also help drive increased adoption. Refer to my other post today:
https://hotcopper.com.au/threads/resapp-fundamentals-general-discussion.5521220/page-69?post_id=46403055In regards to your question on whether Coviu is actively promoting ResAppDx, I haven't seen any such activities. I think that's an area which can be, and needs to be, improved. However, like I said before in my past posts, doctors don't listen to corporate promotions, they listen to their patients' word of mouth. I think a patient-initiated grassroot campaign will be required, and will be more effective and persuasive to doctors for adoption of ResAppDx (and Sleepcheck). Please refer to my previous post:
https://hotcopper.com.au/threads/the-reappdx-sleepcheck-grassroot-campaign.5493966/
